1. The BCR–ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Issue 9 (September 2013) Authors: Malcikova, Jitka; Razga, Filip; Jurcek, Tomas; Dvorakova, Dana; Zackova, Daniela; Toskova, Martina; Sebejova, Ludmila; Smardova, Jana; Oltova, Alexandra; Vankova, Gabriela; Jurackova, Lenka; Trbusek, Martin; Pospisilova, Sarka; Mayer, Jiri; Racil, Zdenek Journal: Leukemia & lymphoma Issue: Volume 54:Issue 9(2013:Sep.) Page Start: 2083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗